Yourgene Health Plc, established in Manchester, UK, in 2000, operates as a molecular diagnostics firm specializing in the research, development, and commercialization of gene analysis technologies. These solutions primarily target prenatal screening and various other diagnostic applications, serving markets across the United Kingdom, continental Europe, and globally. Their product portfolio features a range of in vitro diagnostic tools, including the IONA Test, a non-invasive prenatal screening (NIPT) method for identifying Down's, Edwards', and Patau's syndromes in pregnant women. They also offer Cystic Fibrosis Screening tests, the Rapid Aneuploidy Analysis for confirmatory diagnosis post-amniocentesis, and a PCR assay for Recurrent Pregnancy Loss that diagnoses the six most common chromosomal abnormalities linked to miscarriage. Additionally, Yourgene provides DPYD genotyping products. Beyond specific tests, the company offers technological platforms like Ranger, designed for sample size selection and enrichment. Their Elucigene DPYD assay is a PCR test used to predict a patient's response to chemotherapy, and they provide the Clarigene SARS-CoV-2 CE-IVD, a PCR assay for routine COVID-19 testing. Yourgene Health also delivers comprehensive genomic services, alongside tools for sample preparation and analysis, bioinformatics, and software solutions. For clinical research organizations, they offer specialized services encompassing DNA, RNA/miRNA, and nucleonic extraction; quantification; genotyping; gene expression; methylation; and microarray analysis. The company, originally named Premaitha Health PLC, adopted its current identity as Yourgene Health Plc in November 2018.